Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015 (2015), Article ID 453020, 13 pages
http://dx.doi.org/10.1155/2015/453020
Research Article

Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms

1Institute for Medical Research, University of Belgrade, 11129 Belgrade, Serbia
2Clinic of Endocrinology, Diabetes and Diseases of Metabolism, Clinical Center of Serbia, 11000 Belgrade, Serbia
3Clinic of Hematology, Clinical Center of Serbia, 11000 Belgrade, Serbia
4Medical Faculty, University of Belgrade, 11000 Belgrade, Serbia
5Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA

Received 26 June 2015; Revised 2 September 2015; Accepted 9 September 2015

Academic Editor: Hannes Neuwirt

Copyright © 2015 Vladan P. Čokić et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Landskron, M. De La Fuente, P. Thuwajit, C. Thuwajit, and M. A. Hermoso, “Chronic inflammation and cytokines in the tumor microenvironment,” Journal of Immunology Research, vol. 2014, Article ID 149185, 19 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. P. C. Heinrich, I. Behrmann, S. Haan, H. M. Hermanns, G. Müller-Newen, and F. Schaper, “Principles of interleukin (IL)-6-type cytokine signalling and its regulation,” The Biochemical Journal, vol. 374, no. 1, pp. 1–20, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. J. J. Babon, L. N. Varghese, and N. A. Nicola, “Inhibition of IL-6 family cytokines by SOCS3,” Seminars in Immunology, vol. 26, no. 1, pp. 13–19, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. S. O'Reilly, M. Ciechomska, R. Cant, and J. M. Van Laar, “Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and fibrosis via gremlin protein,” The Journal of Biological Chemistry, vol. 289, no. 14, pp. 9952–9960, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Heikkilä, S. Ebrahim, and D. A. Lawlor, “Systematic review of the association between circulating interleukin-6 (IL-6) and cancer,” European Journal of Cancer, vol. 44, no. 7, pp. 937–945, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Mirantes, E. Passegué, and E. M. Pietras, “Pro-inflammatory cytokines: emerging players regulating HSC function in normal and diseased hematopoiesis,” Experimental Cell Research, vol. 329, no. 2, pp. 248–254, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. K. E. Panteli, E. C. Hatzimichael, P. K. Bouranta et al., “Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases,” British Journal of Haematology, vol. 130, no. 5, pp. 709–715, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Tefferi, R. Vaidya, D. Caramazza, C. Finke, T. Lasho, and A. Pardanani, “Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study,” Journal of Clinical Oncology, vol. 29, no. 10, pp. 1356–1363, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. H.-C. Hsu, W.-H. Tsai, M.-L. Jiang et al., “Circulating levels of thrombopoietic and inflammatory cytokines in patients with clonal and reactive thrombocytosis,” Journal of Laboratory and Clinical Medicine, vol. 134, no. 4, pp. 392–397, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Wickenhauser, J. Thiele, J. Lorenzen et al., “Polycythemia vera megakaryocytes but not megakaryocytes from normal controls and patients with smokers polyglobuly spontaneously express IL-6 and IL-6R and secrete IL-6,” Leukemia, vol. 13, no. 3, pp. 327–334, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Lee, H.-K. Lim, J. Sakong, Y.-S. Lee, J.-R. Kim, and S.-H. Baek, “Janus kinase-signal transducer and activator of transcription mediates phosphatidic acid-induced interleukin (IL)-1β and IL-6 production,” Molecular Pharmacology, vol. 69, no. 3, pp. 1041–1047, 2006. View at Google Scholar · View at Scopus
  12. M. Colomiere, A. C. Ward, C. Riley et al., “Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas,” British Journal of Cancer, vol. 100, no. 1, pp. 134–144, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. T. L. Lee, J. Yeh, C. Van Waes, and Z. Chen, “Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas,” Molecular Cancer Therapeutics, vol. 5, no. 1, pp. 8–19, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Quintás-Cardama, K. Vaddi, P. Liu et al., “Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms,” Blood, vol. 115, no. 15, pp. 3109–3117, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Kirabo, S. O. Park, A. Majumder et al., “The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow,” Neoplasia, vol. 13, no. 11, pp. 1058–1068, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Lee, J.-I. Oh, J. Park et al., “TNF α mediated IL-6 secretion is regulated by JAK/STAT pathway but not by MEK phosphorylation and AKT phosphorylation in U266 multiple myeloma cells,” BioMed Research International, vol. 2013, Article ID 580135, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Guglielmelli, R. Zini, C. Bogani et al., “Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1),” Stem Cells, vol. 25, no. 1, pp. 165–173, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. L. C. Jones, A. Tefferi, P. T. Vuong, J. C. Desmond, W.-K. Hofmann, and H. P. Koeffler, “Detection of aberrant gene expression in CD34+ hematopoietic stem cells from patients with agnogenic myeloid metaplasia using oligonucleotide microarrays,” Stem Cells, vol. 23, no. 5, pp. 631–637, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. U. Steidl, T. Schroeder, C. Steidl et al., “Distinct gene expression pattern of malignant hematopoietic stem and progenitor cells in polycythemia vera,” Annals of the New York Academy of Sciences, vol. 1044, pp. 94–108, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Tefferi, E. Rumi, G. Finazzi et al., “Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study,” Leukemia, vol. 27, no. 9, pp. 1874–1881, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Bonicelli, K. Abdulkarim, M. Mounier et al., “Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients,” British Journal of Haematology, vol. 160, no. 2, pp. 251–254, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Barbui, A. Carobbio, F. Cervantes et al., “Thrombosis in primary myelofibrosis: incidence and risk factors,” Blood, vol. 115, no. 4, pp. 778–782, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Enblom, E. Lindskog, H. Hasselbalch et al., “High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms,” European Journal of Internal Medicine, vol. 26, no. 5, pp. 344–347, 2015. View at Publisher · View at Google Scholar
  24. E. Pourcelot, C. Trocme, J. Mondet, S. Bailly, B. Toussaint, and P. Mossuz, “Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications,” Experimental Hematology, vol. 42, no. 5, pp. 360–368, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Passamonti, L. Vanelli, L. Malabarba et al., “Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders,” Haematologica, vol. 88, no. 10, pp. 1123–1129, 2003. View at Google Scholar · View at Scopus
  26. F. Passamonti, E. Rumi, D. Pietra et al., “Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders,” Blood, vol. 107, no. 9, pp. 3676–3682, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. H. C. Hasselbalch, “Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?” Blood, vol. 119, no. 14, pp. 3219–3225, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. S.-Y. Kim, J. W. Kang, X. Song et al., “Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells,” Cellular Signalling, vol. 25, no. 4, pp. 961–969, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Kothari, R. Pestana, R. Mesraoua et al., “IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAK-dependent IL-10 expression in macrophages,” The Journal of Immunology, vol. 192, no. 1, pp. 349–357, 2013. View at Publisher · View at Google Scholar
  30. C.-C. Duo, F.-Y. Gong, X.-Y. He et al., “Soluble calreticulin induces tumor necrosis factor-α (TNF-α) and interleukin (IL)-6 production by macrophages through mitogen-activated protein kinase (MAPK) and NFκB signaling pathways,” International Journal of Molecular Sciences, vol. 15, no. 2, pp. 2916–2928, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Fourouclas, J. Li, D. C. Gilby et al., “Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders,” Haematologica, vol. 93, no. 11, pp. 1635–1644, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. J. L. Zhao, D. S. Rao, M. P. Boldin, K. D. Taganov, R. M. O'Connell, and D. Baltimore, “NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 22, pp. 9184–9189, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Rameshwar, R. Narayanan, J. Qian, T. N. Denny, C. Colon, and P. Gascon, “NF-κB as a central mediator in the induction of TGF-β in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis,” Journal of Immunology, vol. 165, no. 4, pp. 2271–2277, 2000. View at Publisher · View at Google Scholar · View at Scopus
  34. E. Komura, C. Tonetti, V. Penard-Lacronique et al., “Role for the nuclear factor kappaB pathway in transforming growth factor-beta1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression,” Cancer Research, vol. 65, no. 8, pp. 3281–3289, 2005. View at Google Scholar · View at Scopus
  35. R. Campanelli, V. Rosti, L. Villani et al., “Evaluation of the bioactive and total transforming growth factor β1 levels in primary myelofibrosis,” Cytokine, vol. 53, no. 1, pp. 100–106, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. O. Bock, J. Höftmann, K. Theophile et al., “Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines,” The American Journal of Pathology, vol. 172, no. 4, pp. 951–960, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. F. P. S. Santos and S. Verstovsek, “JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?” Anti-Cancer Agents in Medicinal Chemistry, vol. 12, no. 9, pp. 1098–1109, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Ishii, E. Bruno, R. Hoffman, and M. Xu, “Involvement of various hematopoietic-cell lineages by the JAK2 V617F mutation in polycythemia vera,” Blood, vol. 108, no. 9, pp. 3128–3134, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. D. J. Deangelo, R. A. Mesa, W. Fiskus et al., “Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis,” British Journal of Haematology, vol. 162, no. 3, pp. 326–335, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Manshouri, Z. Estrov, A. Quintás-Cardama et al., “Bone marrow stroma-secreted cytokines protect JAK2V617F-mutated cells from the effects of a JAK2 inhibitor,” Cancer Research, vol. 71, no. 11, pp. 3831–3840, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. G. Garcia-Manero, G. Gartenberg, D. P. Steensma et al., “A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome,” American Journal of Hematology, vol. 89, no. 9, pp. E156–E162, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Z. Orlowski, L. Gercheva, C. Williams et al., “A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma,” American Journal of Hematology, vol. 90, no. 1, pp. 42–49, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. J. San-Miguel, J. Bladé, O. Shpilberg et al., “Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma,” Blood, vol. 123, no. 26, pp. 4136–4142, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. P. M. Voorhees, R. F. Manges, P. Sonneveld et al., “A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma,” British Journal of Haematology, vol. 161, no. 3, pp. 357–366, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. D. C. Polacek, A. G. Passerini, C. Shi et al., “Fidelity and enhanced sensitivity of differential transcription profiles following linear amplification of nanogram amounts of endothelial mRNA,” Physiological Genomics, vol. 13, no. 2, pp. 147–156, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. M. G. Carter, T. Hamatani, A. A. Sharov et al., “In situ-synthesized novel microarray optimized for mouse stem cell and early developmental expression profiling,” Genome Research, vol. 13, no. 5, pp. 1011–1021, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Klur, K. Toy, M. P. Williams, and U. Certa, “Evaluation of procedures for amplification of small-size samples for hybridization on microarrays,” Genomics, vol. 83, no. 3, pp. 508–517, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. A. L. Feldman, N. G. Costouros, E. Wang et al., “Advantages of mRNA amplification for microarray analysis,” BioTechniques, vol. 33, no. 4, pp. 906–914, 2002. View at Google Scholar · View at Scopus